US · OPK · BIOTECHNOLOGY
OPKO Health, Inc. (OPK) intrinsic value and stock valuation
$1.57as of 2026-11-21 · Mkt cap 1.02B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
OPKO Health, Inc. DCF and intrinsic value
InvestorsCraft values OPK with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OPK’s statements →
OPKO Health, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $606.9M | $713.1M | $863.5M | $1B | $1.77B |
| Operating income | -$-218.99M | -$-152.06M | -$-157.02M | -$-226.25M | $18.8M |
| Net income | -$-225.68M | -$-53.22M | -$-188.86M | -$-328.4M | -$-30.14M |
| EPSd | -$-300.45K | -$-76.68K | -$-251.22K | -$-456.71K | -$-46.51K |
| Operating cash flow | -$-178.54M | -$-183.49M | -$-28.2M | -$-95.19M | $38.3M |
| Capital expenditure | -$-12.28M | -$-25.01M | -$-16.27M | -$-24.58M | -$-32.16M |
| Free cash flow | -$-190.82M | -$-208.5M | -$-44.47M | -$-119.77M | $6.18M |
| Total assets | $1.93B | $2.2B | $2.01B | $2.17B | $2.4B |
| Total debt | $433.6M | $504.4M | $326.6M | $305.6M | $254.8M |
| Net debt | $64.5M | $72.5M | $230.7M | $152.4M | $120.1M |
| Total equity | $1.27B | $1.37B | $1.39B | $1.56B | $1.69B |
| Cash and short-term investments | $369.1M | $431.9M | $95.9M | $153.2M | $134.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $606.9M | $713.1M | $863.5M | $1B | $1.77B |
| Cost of revenue | $478.8M | $402.1M | $545.4M | $716M | $1.19B |
| Gross profit | $128.1M | $311M | $318.1M | $288.2M | $581.5M |
| Research and development expenses | $124M | $105.2M | $89.6M | $73.9M | $76.9M |
| Selling, general and administrative expenses | $223M | $304.2M | $300.6M | $372.7M | $468.9M |
| Other expenses | $0.00 | $53.7M | $85M | $67.9M | $17.1M |
| Operating expenses | $347M | $463.1M | $475.2M | $514.5M | $562.8M |
| Cost and expenses | $825.9M | $865.2M | $1.02B | $1.23B | $1.76B |
| Interest income | $14.8M | $8.43M | $3.98M | $1.98M | $30K |
| Interest expense | $108.5M | $47.5M | $13.5M | $12.1M | $18.9M |
| Depreciation and amortization | $91.6M | $98.2M | $105.3M | $108.7M | $78.7M |
| Ebitda | -$-41.3M | $135.3M | -$-65.52M | -$-270.81M | $83.6M |
| Operating income | -$-218.99M | -$-152.06M | -$-157.02M | -$-226.25M | $18.8M |
| Total other income/expenses, net | -$-22.41M | $141.7M | -$-27.41M | -$-165.65M | -$-33.4M |
| Income before tax | -$-241.39M | -$-10.36M | -$-184.43M | -$-391.9M | -$-14.65M |
| Income tax expense | -$-15.71M | $42.8M | $4.44M | -$-63.5M | $15.5M |
| Net income | -$-225.68M | -$-53.22M | -$-188.86M | -$-328.4M | -$-30.14M |
| Weighted average shares outstanding | $751.1M | $694M | $751.8M | $719.1M | $648.1M |
| Weighted average diluted shares outstanding | $751.1M | $694M | $751.8M | $719.1M | $648.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $369.1M | $431.9M | $95.9M | $153.2M | $134.7M |
| Net receivables | $126.1M | $152.1M | $130.2M | $148.6M | $265.6M |
| Inventory | $65.8M | $56.8M | $65.7M | $74.1M | $86.5M |
| Total current assets | $581.9M | $662.1M | $309.5M | $394.5M | $823M |
| Property, plant and equipment, net | $120.9M | $124.1M | $143.5M | $121.6M | $124M |
| Goodwill and intangible assets | $1B | $1.34B | $1.53B | $1.61B | $1.43B |
| Long-term investments | $14.2M | $54.6M | $16.1M | $28.1M | $10.7M |
| Total non-current assets | $1.35B | $1.54B | $1.7B | $1.77B | $1.58B |
| Total assets | $1.93B | $2.2B | $2.01B | $2.17B | $2.4B |
| Accounts payable | $41.1M | $47.1M | $69.7M | $67M | $82M |
| Short-term debt | $22.9M | $29.4M | $43.1M | $51M | $28.6M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $260K |
| Total current liabilities | $146.7M | $193.1M | $200.1M | $213.5M | $330M |
| Long-term debt | $410.7M | $475.1M | $283.5M | $254.5M | $226.2M |
| Deferred revenue, non-current | $0.00 | $10K | $10K | $140K | $210K |
| Total non-current liabilities | $517.3M | $641.7M | $422.4M | $392.1M | $384.6M |
| Capital lease obligations | $40.2M | $67.2M | $77.2M | $49.5M | $49.9M |
| Total liabilities | $664M | $834.8M | $622.5M | $605.6M | $714.6M |
| Common stock | $7.9M | $7.01M | $7.82M | $7.81M | $6.9M |
| Retained earnings | -$-2.29B | -$-2.07B | -$-2.01B | -$-1.82B | -$-1.51B |
| Accumulated other comprehensive income (loss) | -$-21.02M | -$-56.13M | -$-38.03M | -$-43.32M | -$-30.5M |
| Total equity | $1.27B | $1.37B | $1.39B | $1.56B | $1.69B |
| Total investments | $14.2M | $54.6M | $16.1M | $28.1M | $10.7M |
| Total debt | $433.6M | $504.4M | $326.6M | $305.6M | $254.8M |
| Net debt | $64.5M | $72.5M | $230.7M | $152.4M | $120.1M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-225.68M | -$-53.22M | -$-188.86M | -$-328.4M | -$-30.14M |
| Depreciation and amortization | $91.6M | $98.2M | $105.3M | $108.7M | $78.7M |
| Stock-based compensation | $10.7M | $11.1M | $11.4M | $18.5M | $13.6M |
| Change in working capital | -$-41.18M | $32.2M | $21.8M | $42.7M | -$-20.48M |
| Accounts receivable | $30.2M | -$-220K | $3.41M | $128.6M | $5.23M |
| Inventory | -$-4.12M | $4.22M | $15.2M | $13.7M | $30.7M |
| Accounts payable | -$-14.22M | -$-20.66M | $2.83M | -$-9.39M | -$-10.85M |
| Net cash provided by operating activities | -$-178.54M | -$-183.49M | -$-28.2M | -$-95.19M | $38.3M |
| Investments in property, plant and equipment | -$-12.28M | -$-25.01M | -$-16.27M | -$-24.58M | -$-32.16M |
| Acquisitions, net | $0.00 | $0.00 | -$-5M | -$-1.76M | -$-6M |
| Net cash used for investing activities | $230.3M | $352.2M | -$-18.2M | $91M | $36M |
| Common stock issued | -$-260K | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-47.04M | -$-90.22M | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-118.06M | $184.2M | -$-11.3M | $23M | -$-10.35M |
| Net change in cash | -$-62.87M | $349.7M | -$-57.31M | $18.5M | $62.5M |
| Cash at end of period | $382.7M | $445.6M | $95.9M | $153.2M | $134.7M |
| Operating cash flow | -$-178.54M | -$-183.49M | -$-28.2M | -$-95.19M | $38.3M |
| Capital expenditure | -$-12.28M | -$-25.01M | -$-16.27M | -$-24.58M | -$-32.16M |
| Free cash flow | -$-190.82M | -$-208.5M | -$-44.47M | -$-119.77M | $6.18M |
Line items
Line items
Line items
About OPKO Health, Inc.
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.
- CEO
- Phillip Frost
- Employees
- 2.28K
- Beta
- 1.48
Explore
Frequently asked questions
What is the intrinsic value of OPKO Health, Inc. (OPK)?
OPKO Health, Inc. (OPK) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is OPK undervalued?
OPK trades at a price of $1.57 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.